[Prognostic value of minimal residual disease detection in multiple myeloma].
Minimal residual disease (MRD) detection methods are important for diagnosis, treatment, and prognosis in multiple myeloma (MM), and include serum free-light chain assay, multiparametric flow cytometry (with ≥ 4 colors; sensitivity ≤ 10(-4)), allele-specific oligonucleotide-polymerase chain reaction (ASO-PCR; sensitivity 10(-5)), and next-generation sequencing (NGS; sensitivity ≤ 10(-6)). Although molecular complete remission in MM can be assessed by ASO-PCR, this technique requires preparation of clonotype-pecific primers for each individual, which is both labor- and time-consuming. The use of NGS for MRD detection in MM provides increased sensitivity and specificity, while overcoming the challenges associated with ASO-PCR. Furthermore, MRD-negativity revealed by NGS is more closely associated with durable remission of MM than that revealed by ASO -PCR.